StockNews.AI
CDXS
StockNews.AI
187 days

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

1. Codexis will report Q4 and FY2024 results on February 27, 2025. 2. Management will host a conference call to discuss financial results. 3. Codexis specializes in enzymatic solutions for therapeutics manufacturing. 4. The company is developing a new RNAi therapeutics manufacturing platform. 5. Codexis' technologies enhance efficiency and reduce waste in pharmaceutical production.

4m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report could stabilize stock but not lead to significant movement, much like previous earnings announcements generally reinforce previous trends.

How important is it?

Earnings announcements typically inform investors about future company prospects, influencing price but not drastically.

Why Short Term?

The earnings announcement's effects are likely to be seen immediately following the release, similar to past reports.

Related Companies

CDXS
February 13, 2025 16:05 ET  | Source: Codexis, Inc. REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 on Thursday, February 27, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635. About CodexisCodexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com. For More Information Investor ContactCarrie McKim(336) 608-9706ir@codexis.com Media ContactLauren Musto(650) 421-8205media@codexis.com

Related News